Abstract
Tuberculosis (TB) infects one-third of the world population. Despite 50 years of available drug treatments, TB continues to increase at a significant rate. The failure to control TB stems in part from the expense of delivering treatment to infected individuals and from complex treatment regimens. Incomplete treatment has fueled the emergence of multi-drug resistant (MDR) strains of Mycobacterium tuberculosis (Mtb). Reducing non-compliance by reducing the duration of chemotherapy will have a great impact on TB control. The development of new drugs that either kill persisting organisms, inhibit bacilli from entering the persistent phase, or convert the persistent bacilli into actively growing cells susceptible to our current drugs will have a positive effect. We are taking a multidisciplinary approach that will identify and characterize new drug targets that are essential for persistent Mtb. Targets are exposed to a battery of analyses including microarray experiments, bioinformatics, and genetic techniques to prioritize potential drug targets from Mtb for structural analysis. Our core structural genomics pipeline works with the individual laboratories to produce diffraction quality crystals of targeted proteins, and structural analysis will be completed by the individual laboratories. We also have capabilities for functional analysis and the virtual ligand screening to identify novel inhibitors for target validation. Our overarching goals are to increase the knowledge of Mtb pathogenesis using the TB research community to drive structural genomics, particularly related to persistence, develop a central repository for TB research reagents, and discover chemical inhibitors of drug targets for future development of lead compounds.
Keywords: free-interface diffusion screening chip, Virtual screening, ATP-phosphoribosyl transferase, Mycolic acid, Pantothenate Synthetase, Arginine Metabolism
Infectious Disorders - Drug Targets
Title: High Throughput Crystallography of TB Drug Targets
Volume: 7 Issue: 2
Author(s): T.R. Ioerger, J.C. Sacchettini, S. Wang, F.Wang, T.C. Terwilliger, B.W. Segelke, R. Sankaranarayanan, J.S. Lott, I. Krieger, C. Kim, M.N.G.James, W.R. Jacobs, A.C. Murillo, L. W. Hung, C.W. Goulding, C.R. Garen, D. Eisenberg, Yoon Song Cho, M.M. Cherney, L.T. Cherney, J.M. Berger, E.N. Baker, T. Alber and H.Y. Li
Affiliation:
Keywords: free-interface diffusion screening chip, Virtual screening, ATP-phosphoribosyl transferase, Mycolic acid, Pantothenate Synthetase, Arginine Metabolism
Abstract: Tuberculosis (TB) infects one-third of the world population. Despite 50 years of available drug treatments, TB continues to increase at a significant rate. The failure to control TB stems in part from the expense of delivering treatment to infected individuals and from complex treatment regimens. Incomplete treatment has fueled the emergence of multi-drug resistant (MDR) strains of Mycobacterium tuberculosis (Mtb). Reducing non-compliance by reducing the duration of chemotherapy will have a great impact on TB control. The development of new drugs that either kill persisting organisms, inhibit bacilli from entering the persistent phase, or convert the persistent bacilli into actively growing cells susceptible to our current drugs will have a positive effect. We are taking a multidisciplinary approach that will identify and characterize new drug targets that are essential for persistent Mtb. Targets are exposed to a battery of analyses including microarray experiments, bioinformatics, and genetic techniques to prioritize potential drug targets from Mtb for structural analysis. Our core structural genomics pipeline works with the individual laboratories to produce diffraction quality crystals of targeted proteins, and structural analysis will be completed by the individual laboratories. We also have capabilities for functional analysis and the virtual ligand screening to identify novel inhibitors for target validation. Our overarching goals are to increase the knowledge of Mtb pathogenesis using the TB research community to drive structural genomics, particularly related to persistence, develop a central repository for TB research reagents, and discover chemical inhibitors of drug targets for future development of lead compounds.
Export Options
About this article
Cite this article as:
T.R. Ioerger , J.C. Sacchettini , S. Wang , F.Wang , T.C. Terwilliger , B.W. Segelke , R. Sankaranarayanan , J.S. Lott , I. Krieger , C. Kim , M.N.G.James , W.R. Jacobs , A.C. Murillo , L. W. Hung , C.W. Goulding , C.R. Garen , D. Eisenberg , Yoon Song Cho , M.M. Cherney , L.T. Cherney , J.M. Berger , E.N. Baker , T. Alber and H.Y. Li , High Throughput Crystallography of TB Drug Targets, Infectious Disorders - Drug Targets 2007; 7 (2) . https://dx.doi.org/10.2174/187152607781001853
DOI https://dx.doi.org/10.2174/187152607781001853 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pulmonary Drug Delivery System: A Novel Approach for Drug Delivery
Current Drug Therapy A Co-Module Regulated by Therapeutic Drugs in a Molecular Subnetwork of Alzheimer’s Disease Identified on the Basis of Traditional Chinese Medicine and SAMP8 Mice
Current Alzheimer Research Developments of Indoles as Anti-HIV-1 Inhibitors
Current Pharmaceutical Design Micronutrient Deficiency in Pulmonary Tuberculosis - Perspective on Hepatic Drug Metabolism and Pharmacokinetic Variability of First-line Anti- Tuberculosis Drugs: Special Reference to Fat-soluble Vitamins A, D, & E and Nutri-epigenetics
Drug Metabolism Letters Synthesis, Antimycobacterial, Antiviral, Antimicrobial Activity and QSAR Studies of N2-acyl isonicotinic Acid Hydrazide Derivatives
Medicinal Chemistry Finding the Smoking Gun: Protein Tyrosine Phosphatases as Tools and Targets of Unicellular Microorganisms and Viruses
Current Medicinal Chemistry Privileged Structures in the Design of Potential Drug Candidates for Neglected Diseases
Current Medicinal Chemistry Bioinformatics and Drug Discovery
Current Topics in Medicinal Chemistry Patents Related to Pathogenic Human Coronaviruses
Recent Patents on Biotechnology Synthesis, Characterization, Antimycobacterial and Anticancer Evaluation of New 1,2,4-Triazole Derivatives
Letters in Drug Design & Discovery Distance Based Genetic Algorithm for Feature Selection in Computer Aided Diagnosis Systems
Current Medical Imaging Pharmacogenomics of Arylamine N-acetyltransferase
Current Pharmacogenomics Microarray Analysis of Whole Genome Expression of Intracellular Mycobacterium tuberculosis
Current Molecular Medicine The Molecular and Pharmacological Mechanisms of HIV-Related Neuropathic Pain
Current Neuropharmacology History and Therapeutic Use of MAO-A Inhibitors: A Historical Perspective of MAO-A Inhibitors As Antidepressant Drug
Current Topics in Medicinal Chemistry Microfluidics as an Emerging Platform for Tackling Antimicrobial Resistance (AMR): A Review
Current Analytical Chemistry From Protein-Protein Interactions to Rational Drug Design: Are Computational Methods Up to the Challenge?
Current Topics in Medicinal Chemistry Antiidiotype-Derived Killer Peptides As New Potential Tools to Combat HIV-1 and AIDS-Related Opportunistic Pathogens
Anti-Infective Agents in Medicinal Chemistry Recombinant Murine Polyoma Virus-like-particles Induce Protective Antitumour Immunity
Letters in Drug Design & Discovery C-Type Lectins on Dendritic Cells and Their Interaction with Pathogen-Derived and Endogenous Glycoconjugates
Current Protein & Peptide Science